Acquisition - September 6, 2021
Investor supports Agnafit Bidco’s bid for Sobi
Investor AB has undertaken to accept the public offer made September 2, by Agnafit Bidco for the shares in Swedish Orphan Biovitrum at a price per share of SEK 235. Investor owns 107.6 million shares in Sobi, representing 35.4 percent of the capital and votes. The offer values Investor’s shares in Sobi at SEK 25.3 […]
Clinical Trials - May 4, 2021
First patient dosed in Sobi’s XTEND-Kids study
Swedish Orphan Biovitrum has announced that the first patient has been dosed in the phase 3, open-label, interventional XTEND-Kids study of efanesoctocog alfa (BIVV001) in paediatric subjects with severe haemophilia A. The XTEND-Kids study is designed to investigate the efficacy, safety and pharmacokinetics of efanesoctocog alfa as once-weekly prophylaxis in approximtately 65 previously treated patients […]
Clinical Trials - October 14, 2020
Sobi study did not meet primary endpoints
Swedish Orphan Biovitrum (Sobi) has announced results from its phase 3 study of avatrombopag, an oral thrombopoietin (TPO) receptor agonist, in solid tumour cancer patients with chemotherapy-induced thrombocytopenia (CIT). Though avatrombopag increased platelet counts relative to placebo as expected, the study did not meet the composite primary endpoint of avoiding platelet transfusions, chemotherapy dose reductions […]
In a new job - September 1, 2020
Sobi appoints new Head of R&D
Swedish Orphan Biovitrum has announced that Ravi Rao has been appointed Head of Research & Development (R&D) as Milan Zdravkovic will pursue other opportunities outside of the company. Ravi joins from Aeglea Biotherapeutics where he has been the Chief Medical Officer. His previous experience includes roles at GSK where he was Vice President, Global Medical […]
Acquisition - September 30, 2019
Sobi to acquire Dova Pharmaceuticals
Swedish Orphan Biovitrum (Sobi) has announced a definitive agreement to acquire Dova Pharmaceuticals by means of a tender offer. The transaction is valued at up to USD 915 million on a fully diluted basis The consideration consists of an upfront payment of USD 27.50 per share in cash and, one non-tradeable Contingent Value Right (CVR). […]
Agreement - August 22, 2019
Sobi sells Priority Review Voucher to AstraZeneca
Swedish Orphan Biovitrum has entered into an agreement to sell a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) to AstraZeneca for a total cash consideration of USD 95 million. A PRV entitles the holder to FDA priority review of a single New Drug Application or Biologics License Application, which reduces the target […]
